The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.
Scientists have uncovered a key mechanism in jellyfish embryos that provides new insights into how the body plan of these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback